STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 w...

por Smith, Timothy R., Winner, Paul, Aurora, Sheena K., Jeleva, Maria, Hocevar‐Trnka, Jasna, Shrewsbury, Stephen B.
Publicado 2021